神威药业(02877.HK)中期纯利增长11.92%至2.88亿元 中期息每股11分
格隆汇8月30日丨神威药业(02877.HK)公布,截至2019年6月30日止六个月,实现营业额人民币13.68亿元(单位下同),同比上升4.8%;毛利9.75亿元,同比增长4.95%;公司拥有人应占期内溢利2.88亿元,同比增长11.92%;每股盈利36分;拟派每股中期股息人民币11分。
于二零一九首六个月,集团零售药店产品销售按内部统计占整体销售额约17.3%,达到2.37亿元。
公告显示,集团的零售药店销售团队正优化连锁药店的覆盖,截至2019年6月底,集团零售药店销售团队覆盖的零售药店终端按内部统计达到14.3万家。其中8.1万家是连锁药店,而6.2万家是单体药店。连锁药店覆盖数量比去年同期减少了1.9万家,单体药店则增加了1.2万家。
据悉,集团目前共有14项研究专案正在陆续进行药学及临床试验。其中包括2种独家创新药物。
其中,集团重点研发的创新组分中药「塞络通胶囊」现于澳洲和中国进行III期临床试验,预计分别于二零二一年及二零二二年完成。澳洲的III期临床试验重点针对治疗血管性痴呆和阿尔茨海默病,而中国的III期临床试验则针对血管性痴呆的治疗。
此外,Q-B-Q-F浓缩丸重点针对治疗儿童支原体肺炎,目前通过绿色通道正开始其III期临床试验,预计2021年完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.